The US Food and Drug Administration has made available a development template with recommendations to streamline emergency use authorizations of screening tests for serial COVID-19 testing, which developers can consider before conducting certain performance evaluations with asymptomatic patients.
If the recommendations are followed, the FDA may grant an EUA for OTC distribution to certain point-of-care or at-home tests without the need to validate the test on asymptomatic patients...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?